IRWD Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A
1,956
$5.95
$0.11
(1.81%)
| Watchers | 1,956 |
| 52-Wk Low | $5.85 |
| 52-Wk High | $15.70 |
| Market Cap | $945.79M |
| Volume | 1.91M |
| 52-Wk High | $15.70 |
| 52-Wk Low | $5.85 |
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)Business Wire • 4 days ago
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week (DDW) meeting from its pivotal Phase III...
Share to Feed
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its first quarter 2024 results and recent business performance. In the first quarter of 2024, we made...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 10:00 a.m. ET...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024...
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has earned a consensus recommendation of "Buy" from the five analysts that are covering the stock, MarketBeat reports. Five equities...
Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) was upgraded by StockNews.com from a "hold" rating to a "buy" rating in a research note issued on Friday.
IRWD has been the subject of a...
Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) and Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) are both medical companies, but which is the superior business? We will compare the...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced positive, primary results up to Day 91 for its Phase II exploratory STARGAZE trial evaluating...
Capital One Financial analyst Tim Chiang maintained a Buy rating on Ironwood Pharma (IRWD Research Report) today and set a price target of $15.00...